NEW YORK, Nov. 2 (GenomeWeb News) - Shares in Third Wave were down 13.2 percent, or $.47, at $3.08 in mid-afternoon trading after the company announced this morning that third-quarter revenue fell by half and net losses grew more than 300 fold.
Already have a GenomeWeb or 360Dx account?Login Now.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.